

2019 Future of Spinal Muscular Atrophy (SMA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2F571727F12EN.html>

Date: February 2019

Pages: 95

Price: US\$ 2,199.00 (Single User License)

ID: 2F571727F12EN

Abstracts

The global demand for Spinal Muscular Atrophy (SMA) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Spinal Muscular Atrophy (SMA) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Spinal Muscular Atrophy (SMA) pipeline companies from advancing their products into Phase 3 or Phase 4.

Spinal Muscular Atrophy (SMA) Report Description-

The 2019 pipeline study on Spinal Muscular Atrophy (SMA) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Spinal Muscular Atrophy (SMA) pipeline compounds.

The Spinal Muscular Atrophy (SMA) pipeline guide presents information on all active drugs currently being developed for Spinal Muscular Atrophy (SMA). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Spinal Muscular Atrophy (SMA) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Spinal Muscular Atrophy (SMA) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Spinal Muscular Atrophy (SMA) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Spinal Muscular Atrophy (SMA) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Spinal Muscular Atrophy (SMA) pipeline report includes-

An overview of Spinal Muscular Atrophy (SMA) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Spinal Muscular Atrophy (SMA) pipeline

Company wise list of Spinal Muscular Atrophy (SMA) pipeline

Mechanism of Action wise Spinal Muscular Atrophy (SMA) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Spinal Muscular Atrophy (SMA) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Spinal Muscular Atrophy (SMA) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Spinal Muscular Atrophy (SMA) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Spinal Muscular Atrophy (SMA) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Spinal Muscular Atrophy (SMA) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Spinal Muscular Atrophy (SMA) Pipeline Candidates

4 ANDROSCIENCE CORP SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 4.1 AndroScience Corp Business Profile
- 4.2 AndroScience Corp Spinal Muscular Atrophy (SMA) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity

- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ARMGO PHARMA INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 5.1 Armgo Pharma Inc Business Profile
- 5.2 Armgo Pharma Inc Spinal Muscular Atrophy (SMA) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AURIMMED PHARMA INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 6.1 AurimMed Pharma Inc Business Profile
- 6.2 AurimMed Pharma Inc Spinal Muscular Atrophy (SMA) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action

6.6 Clinical/Pre-clinical Trial Details

6.7 Latest Drug Developments

7 AVEXIS INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

7.1 AveXis Inc Business Profile

7.2 AveXis Inc Spinal Muscular Atrophy (SMA) Drug Details

7.3 Drug Snapshot

7.3.1 Originator

7.3.2 Collaborator/Co-Developer

7.3.3 Route of Administration

7.3.4 Orphan Drug/Fast Track/Special Designation

7.3.5 Geography

7.3.6 Type of Molecular Entity

7.3.7 Current Status

7.4 Drug Overview

7.5 Drug Mechanism of Action

7.6 Clinical/Pre-clinical Trial Details

7.7 Latest Drug Developments

8 BIOGEN INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

8.1 Biogen Inc Business Profile

8.2 Biogen Inc Spinal Muscular Atrophy (SMA) Drug Details

8.3 Drug Snapshot

8.3.1 Originator

8.3.2 Collaborator/Co-Developer

8.3.3 Route of Administration

8.3.4 Orphan Drug/Fast Track/Special Designation

8.3.5 Geography

8.3.6 Type of Molecular Entity

8.3.7 Current Status

8.4 Drug Overview

8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9 BIOMARIN PHARMACEUTICAL INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 9.1 BioMarin Pharmaceutical Inc Business Profile
- 9.2 BioMarin Pharmaceutical Inc Spinal Muscular Atrophy (SMA) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CYTOKINETICS INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 10.1 Cytokinetics Inc Business Profile
- 10.2 Cytokinetics Inc Spinal Muscular Atrophy (SMA) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 EXICURE INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 11.1 Exicure Inc Business Profile
- 11.2 Exicure Inc Spinal Muscular Atrophy (SMA) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator

- 11.3.2 Collaborator/Co-Developer
- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 F. HOFFMANN-LA ROCHE LTD SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 12.1 F. Hoffmann-La Roche Ltd Business Profile
- 12.2 F. Hoffmann-La Roche Ltd Spinal Muscular Atrophy (SMA) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 GENEА BIOCELLS SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 13.1 Genea Biocells Business Profile
- 13.2 Genea Biocells Spinal Muscular Atrophy (SMA) Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography

- 13.3.6 Type of Molecular Entity
- 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 GENETHON SA SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 14.1 Genethon SA Business Profile
- 14.2 Genethon SA Spinal Muscular Atrophy (SMA) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 GNT PHARMA CO LTD SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 15.1 GNT Pharma Co Ltd Business Profile
- 15.2 GNT Pharma Co Ltd Spinal Muscular Atrophy (SMA) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 KOWA CO LTD SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

16.1 Kowa Co Ltd Business Profile

16.2 Kowa Co Ltd Spinal Muscular Atrophy (SMA) Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 NEURODYN LIFE SCIENCES INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

17.1 Neurodyn Life Sciences Inc Business Profile

17.2 Neurodyn Life Sciences Inc Spinal Muscular Atrophy (SMA) Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18 NEUROTUNE AG SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 18.1 Neurotune AG Business Profile
- 18.2 Neurotune AG Spinal Muscular Atrophy (SMA) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 NOVARTIS AG SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 19.1 Novartis AG Business Profile
- 19.2 Novartis AG Spinal Muscular Atrophy (SMA) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 ONO PHARMACEUTICAL CO LTD SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 20.1 Ono Pharmaceutical Co Ltd Business Profile
- 20.2 Ono Pharmaceutical Co Ltd Spinal Muscular Atrophy (SMA) Drug Details
- 20.3 Drug Snapshot

- 20.3.1 Originator
- 20.3.2 Collaborator/Co-Developer
- 20.3.3 Route of Administration
- 20.3.4 Orphan Drug/Fast Track/Special Designation
- 20.3.5 Geography
- 20.3.6 Type of Molecular Entity
- 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 PARATEK PHARMACEUTICALS INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 21.1 Paratek Pharmaceuticals Inc Business Profile
- 21.2 Paratek Pharmaceuticals Inc Spinal Muscular Atrophy (SMA) Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 REBORNA BIOSCIENCES INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 22.1 Reborna Biosciences Inc Business Profile
- 22.2 Reborna Biosciences Inc Spinal Muscular Atrophy (SMA) Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration

- 22.3.4 Orphan Drug/Fast Track/Special Designation
- 22.3.5 Geography
- 22.3.6 Type of Molecular Entity
- 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 RECURSION PHARMACEUTICALS INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 23.1 Recursion Pharmaceuticals Inc Business Profile
- 23.2 Recursion Pharmaceuticals Inc Spinal Muscular Atrophy (SMA) Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 SAREPTA THERAPEUTICS INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 24.1 Sarepta Therapeutics Inc Business Profile
- 24.2 Sarepta Therapeutics Inc Spinal Muscular Atrophy (SMA) Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity

- 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 SCHOLAR ROCK INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 25.1 Scholar Rock Inc Business Profile
- 25.2 Scholar Rock Inc Spinal Muscular Atrophy (SMA) Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator
 - 25.3.2 Collaborator/Co-Developer
 - 25.3.3 Route of Administration
 - 25.3.4 Orphan Drug/Fast Track/Special Designation
 - 25.3.5 Geography
 - 25.3.6 Type of Molecular Entity
 - 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 SHIFT PHARMACEUTICALS SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

- 26.1 Shift Pharmaceuticals Business Profile
- 26.2 Shift Pharmaceuticals Spinal Muscular Atrophy (SMA) Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action

26.6 Clinical/Pre-clinical Trial Details

26.7 Latest Drug Developments

27 SPOTLIGHT INNOVATION INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

27.1 Spotlight Innovation Inc Business Profile

27.2 Spotlight Innovation Inc Spinal Muscular Atrophy (SMA) Drug Details

27.3 Drug Snapshot

27.3.1 Originator

27.3.2 Collaborator/Co-Developer

27.3.3 Route of Administration

27.3.4 Orphan Drug/Fast Track/Special Designation

27.3.5 Geography

27.3.6 Type of Molecular Entity

27.3.7 Current Status

27.4 Drug Overview

27.5 Drug Mechanism of Action

27.6 Clinical/Pre-clinical Trial Details

27.7 Latest Drug Developments

28 VYBION INC SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DETAILS

28.1 Vybion Inc Business Profile

28.2 Vybion Inc Spinal Muscular Atrophy (SMA) Drug Details

28.3 Drug Snapshot

28.3.1 Originator

28.3.2 Collaborator/Co-Developer

28.3.3 Route of Administration

28.3.4 Orphan Drug/Fast Track/Special Designation

28.3.5 Geography

28.3.6 Type of Molecular Entity

28.3.7 Current Status

28.4 Drug Overview

28.5 Drug Mechanism of Action

28.6 Clinical/Pre-clinical Trial Details

28.7 Latest Drug Developments

29. LATEST SPINAL MUSCULAR ATROPHY (SMA) DRUG PIPELINE

DEVELOPMENTS, 2019

30. APPENDIX

30.1 About Us

30.2 Sources and Methodology

30.3 Contact Information

I would like to order

Product name: 2019 Future of Spinal Muscular Atrophy (SMA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2F571727F12EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F571727F12EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970